阿斯利康PD-L1单抗一项III期研究成功

医药魔方2025-05-09

5月9日，阿斯利康宣布Imfinzi（度伐利尤单抗）联合标准治疗（SOC）治疗高危非肌层浸润性膀胱癌（NMIBC）患者的III期POTOMAC研究取得了积极的高水平结果。该研究是一项随机、开放标签、多中心、全球性临床试验（n=1018），评估了Imfinzi联合卡介苗（BCG）治疗接受过经尿道膀胱肿瘤切除术（TURBT）但未接受过BCG治疗的高危NMIBC患者的疗效和安全性。患者被随机平均分为三组...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2534120879?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-05-09 15:39","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2534120879","market":"us","top_or_hot":-1,"title":"阿斯利康PD-L1单抗一项III期研究成功","media":"医药魔方","content":"<div>\n<p>5月9日，阿斯利康宣布Imfinzi（度伐利尤单抗）联合标准治疗（SOC）治疗高危非肌层浸润性膀胱癌（NMIBC）患者的III期POTOMAC研究取得了积极的高水平结果。该研究是一项随机、开放标签、多中心、全球性临床试验（n=1018），评估了Imfinzi联合卡介苗（BCG）治疗接受过经尿道膀胱肿瘤切除术（TURBT）但未接受过BCG治疗的高危NMIBC患者的疗效和安全性。患者被随机平均分为三组...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509155609a6d8c3f4&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>阿斯利康PD-L1单抗一项III期研究成功</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n阿斯利康PD-L1单抗一项III期研究成功\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-05-09 15:39 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509155609a6d8c3f4&s=b><strong>医药魔方</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>5月9日，阿斯利康宣布Imfinzi（度伐利尤单抗）联合标准治疗（SOC）治疗高危非肌层浸润性膀胱癌（NMIBC）患者的III期POTOMAC研究取得了积极的高水平结果。该研究是一项随机、开放标签、多中心、全球性临床试验（n=1018），评估了Imfinzi联合卡介苗（BCG）治疗接受过经尿道膀胱肿瘤切除术（TURBT）但未接受过BCG治疗的高危NMIBC患者的疗效和安全性。患者被随机平均分为三组...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509155609a6d8c3f4&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2462157665.USD","symbol_name":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509155609a6d8c3f4&s=b","article_id":"2534120879","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509155609a6d8c3f4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2534120879","pubTimestamp":1746776382,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"5月9日，阿斯利康宣布Imfinzi联合标准治疗治疗高危非肌层浸润性膀胱癌患者的III期POTOMAC研究取得了积极的高水平结果。结果显示，治疗一年后，与BCG组相比，度伐利尤单抗+BCG组患者的无疾病生存期显著延长且具有临床意义。膀胱癌是世界上第九大最常见的癌症，全球每年有超过61.4万例新诊断病例。目前NMIBC的SOC是TURBT术后+BCG。高达80%的患者在5年内出现疾病复发，高危患者的疾病进展率可高达45%。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4134":"信息科技咨询与其它服务","PD":"PagerDuty, Inc.","BK4007":"制药","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","III":"信息服务","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","BK4023":"应用软件","BK4585":"ETF&股票定投概念","BK4588":"碎股","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU1829250122.USD":"高盛欧洲核心股票组合Acc","AZN":"阿斯利康","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","BK4568":"美国抗疫概念"},"translate_title":"A phase III study of AstraZeneca PD-L1 monoclonal antibody was successful","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PD":1,"AZN":1,"III":1},"content_text":"5月9日，阿斯利康宣布Imfinzi（度伐利尤单抗）联合标准治疗（SOC）治疗高危非肌层浸润性膀胱癌（NMIBC）患者的III期POTOMAC研究取得了积极的高水平结果。该研究是一项随机、开放标签、多中心、全球性临床试验（n=1018），评估了Imfinzi联合卡介苗（BCG）治疗接受过经尿道膀胱肿瘤切除术（TURBT）但未接受过BCG治疗的高危NMIBC患者的疗效和安全性。患者被随机平均分为三组：①Imfinzi+BCG作为诱导治疗和维持治疗，②Imfinzi+BCG作为诱导治疗，③BCG作为诱导治疗和维持治疗。结果显示，治疗一年后，与BCG（诱导治疗和维持治疗）组相比，度伐利尤单抗+BCG（诱导治疗和维持治疗）组患者的无疾病生存期（DFS）显著延长且具有临床意义。该研究尚未到达评估总生存期（OS）的节点，不过描述性分析表明患者的生存期没有受到损害。此外，与BCG（诱导治疗和维持治疗）组相比，度伐利尤单抗+BCG（诱导治疗）组未达到DFS显著延长的主要终点。Imfinzi已在全球范围内获批9项适应症，其中包括术前联合吉西他滨和顺铂并在术后单药治疗肌层浸润性膀胱癌（MIBC）。膀胱癌是世界上第九大最常见的癌症，全球每年有超过61.4万例新诊断病例。超过70%的膀胱癌患者被诊断为NMIBC，这是膀胱癌的早期阶段——肿瘤位于膀胱内表面的组织中，但尚未侵入肌肉壁。大约一半的NMIBC患者因其癌症的某些特征（例如肿瘤分级、分期和特定的肿瘤特征）而被归类为疾病进展或复发风险高。目前NMIBC的SOC是TURBT术后+BCG。高达80%的患者在5年内出现疾病复发，高危患者的疾病进展率可高达45%。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2534120879","isCrawlerRequest":true}